進階搜尋


下載電子全文  
系統識別號 U0026-2301201311085600
論文名稱(中文) 芝麻油對非酒精性脂肪肝炎導致小鼠肝纖維化的保護作用
論文名稱(英文) The protective effect of sesame oil against nonalcoholic steatohepatitis induced hepatic fibrosis in mice
校院名稱 成功大學
系所名稱(中) 環境醫學研究所
系所名稱(英) Institute of Environmental and Occupational Health
學年度 101
學期 1
出版年 102
研究生(中文) 張伯誠
研究生(英文) Po-Cheng Chang
電子信箱 s76981092@mail.ncku.edu.tw
學號 s76981092
學位類別 碩士
語文別 中文
論文頁數 75頁
口試委員 指導教授-劉明毅
口試委員-許德榮
口試委員-張志欽
口試委員-郭余民
口試委員-鄭宏祺
中文關鍵字 非酒精性脂肪肝炎  脂肪變性  氧化性壓力  發炎反應  肝纖維化 
英文關鍵字 NASH  steatosis  oxidative stress  inflammation  hepatic fibrosis 
學科別分類
中文摘要 非酒精性脂肪肝炎是慢性肝臟疾病,根據流行病學統計,西方國家及台灣,非酒精性脂肪肝炎的盛行率大約3-15%,脂肪變性、氧化性壓力和發炎反應是造成非酒精性脂肪肝炎的重要因子,非酒精性脂肪肝炎長期發展可能嚴重惡化為肝纖維化、肝硬化及肝癌。芝麻油是常見的食用油與保健食品,具有抗脂肪變性、抗氧化及抗發炎的能力,但是對於非酒精性脂肪肝炎導致肝纖維化的影響仍不清楚。本研究探討芝麻油對非酒精性脂肪肝炎導致小鼠肝纖維化之保護作用。將小鼠餵食甲硫胺酸及膽鹼缺乏飼料21天,成功建立非酒精脂肪肝炎動物模式後,繼續餵食甲硫胺酸及膽鹼缺乏飼料到28天或到35天,誘導出不同程度的非酒精性脂肪肝炎導致的肝纖維化,從第22天至第28天或第29天至第35天,分別以口服方式每日一次利用灌食針餵予小鼠不同劑量(1, 2, 4 ml/kg/day)的芝麻油,再於隔天收集小鼠血液及肝臟,進行芝麻油對不同等級之非酒精性脂肪肝炎導致肝纖維化的作用分析。餵食21天甲硫胺酸及膽鹼缺乏的飼料可以提高脂肪變性、三酸甘油脂、一氧化氮、丙二醛、腫瘤壞死因子-α及細胞白介素第6因子的含量,而且降低過氧化物酵素增殖激活受體-α。從第22天至28天每天一次連續七天餵予芝麻油,可以降低一氧化氮、丙二醛、腫瘤壞死因子-α、細胞白介素第6因子、細胞白介素第1β因子、瘦體素及轉化生長因子-β,顯示芝麻油可以避免造成非酒精性肝炎導致的肝纖維化;從第29天至35天每天一次連續七天餵予芝麻油,可以降低基質金屬蛋白酶-2及-9的酵素活性、提高基質金屬蛋白酶組織抑制因子-1及過氧化物酵素增殖激活受體-γ的含量,顯示芝麻油也可以抑制非酒精性脂肪肝炎引起肝纖維化的進一步惡化。總結,芝麻油可以有效防治非酒精性脂肪肝炎導致的小鼠肝纖維化。
英文摘要 Nonalcoholic steatohepatitis (NASH) is a chronic liver disease. In Western countries and Taiwan, the prevalence of NASH is 3-15%. Steatosis, oxidative stress and inflammation are major risk factors in NASH by which may lead to fibrosis, cirrhosis, and hepatic carcinoma. Sesame oil is a potent functional food with anti-steatosis, anti-oxidation, and anti-inflammation against various diseases. The protective effect of sesame oil against NASH-induced hepatic fibrosis was unclear. The study examined the effect of sesame oil against NASH-induced hepatic fibrosis in mice. Mice were fed with methionine and choline deficient (MCD) diet for 21 days to induce NASH and for 28 or 35 days to induce different grade of hepatic fibrosis. Seven doses of sesame oil (1, 2,or 4 ml/kg/day) were given orally from 22nd to 28th and 29th to 35th days, respectively. Those mice were killed one day after sesame oil was given and serum and tissue were collected to examine the effect of sesame oil on NASH-induced hepatic fibrosis. Mice were fed with MCD diet to induce NASH by increasing steatosis, triglyceride, nitric oxide, malonaldehyde, tumor necrosis factor-α, and interleukin-6, but decreasing peroxisome proliferator activated receptors-α. Sesame oil decreased NASH-induced nitric oxide, malonaldehyde, tumor necrosis factor-α, interleukin-6, interleukin-1β, leptin, transforming growth factor-β, matrix metalloproteinase-2, matrix metalloproteinase-9, but increased tissue inhibitor of matrix metalloproteinase-1 and peroxisome proliferator activated receptors-γ. This indicated that sesame oil given from 22nd to 28th days prevented from NASH-induced hepatic fibrosis. In addition, sesame oil given from 29th to 35th days inhibited the progression of NASH-induced hepatic fibrosis. In conclusion, sesame oil protected against NASH-induced hepatic fibrosis in mice.
論文目次 中文摘要 1
英文摘要 2
誌謝 3
目次 4
圖目錄 5
表目錄 6
研究背景 7~16
研究目的 17
材料與方法 18~32
結果 33~38
討論 39~43
結論 44
參考文獻 45~62
實驗圖表 63~75
參考文獻 Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. 2011. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. The Journal of Nutrition. 141:603-610.
Adams LA, Angulo P. 2006. Treatment of non-alcoholic fatty liver disease. Postgraduate Medical Journal. 82:315-322.
Alba FS, Eduardo MS, Mirandeli B, Jaime ES, Ángel MG, Cesar EC, Irene DM, Graciela SR, Carmen VV, José A, Morales G. 2011. Inflammation, oxidative Stress, and obesity. International Journal of Molecular Sciences. 12:3117-3132.
Ali A, Moazzami, Stefanie LH, Afaf KE. 2007. Lignan contents in sesame seeds and products. European Journal of Lipid Science and Technology. 109:1022-1027.
Andersen T, Gluud C, Franzmann MB, Christoffersen P. 1991. Hepatic effects of dietary weight loss in morbidly obese subjects. Journal of Hepatology. 12:224-229.
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ and Goh KL. 2007. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? Journal of Gastroenterology and Hepatology. 22:788-793.
Angulo P. 2002. Nonalcoholic fatty liver disease. The New England Journal of Medicine. 346:1221-1231.
Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. 2004. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. Hippokratia. 41:943-949.
Anilakumar KR. 2010. Nutritional, medicinal and industrial uses of sesame (Sesamum indicum L.) seeds - An Overview. Agriculturae Conspectus Scientificus. 75:159-168.
Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. 2009. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? Journal of Clinical Gastroenterology. 43:565-568.
Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. 2006. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obesity Surgery. 16:1351-1358.
Atherton HJ, Gulston MK, Bailey NJ, Cheng KK, Zhang W, Clarke K, Griffin JL. 2009. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Molecular Systems Biology. 5:259.
Bailey CJ, Turner RC. 1996. Metformin. The New England Journal of Medicine. 334:574-579.
Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. 2001. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:3046-3051.
Bánhegyi G, Baumeister P, Benedetti A, Dong D, Fu Y, Lee AS, Li J, Mao C, Margittai E, Ni M, Paschen W, Piccirella S, Senesi S, Sitia R, Wang M, Yang W. 2007. Endoplasmic reticulum stress. Annals of The New York Academy of Sciences. 1113:58-71.
Banni S, Corongiu FP, Dessi MA, Iannone A, Lombardi B, Tomasi A, Vannini V. 1989. Free radicals and lipid peroxidation in liver of rats kept on a diet devoid of choline. Free Radical Research Communications. 7:233-240.
Basaranoglu M, Acbay O, Sonsuz A. 1999. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. Journal of Hepatology. 1:384.
Bataller R, Rombouts K, Altamirano J, Marra F. 2011. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Practice and Research Clinical Gastroenterology. 25:231-244.
Baydar H, Turgut İ, Turgut K. 1999. Variation of certain characters and line selection for yield, oil, oleic and linoleic acids in Turkish sesame (Sesamum indicum L.) populations. Turkish Journal of Agriculture and Forestry. 23:431-441.
Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature Medicine. 11:183-190.
Chang CY, Chen YL, Yang SC, Huang GC, Tsi D, Huang CC, Chen JR, Li JS. 2009. Effect of schisandrin B and sesamin mixture on CCl(4)-induced hepatic oxidative stress in rats. Phytotherapy Research. 23:251-256.
Chen WL, Lu HC, Huang HY, Hwang GY, Jason T. 2010. Sesame lignans significantly alleviate liver damage of rats caused by carbon tetrachloride in combination with kava. Journal of Food and Drug Analysis. 18:249-255.
Chu PY, Chien SP, Hsu DZ, Liu MY. 2010. Protective effect of sesamol on the pulmonary inflammatory response and lung injury in endotoxemic rats. Food and Chemical Toxicology. 48:1821-1826.
Chu PY, Srinivasan P, Deng JF, Liu MY. 2012. Sesamol attenuates oxidative stress-mediated experimental acute pancreatitis in rats. Human and Experimental Toxicology. 31:397-404.
Clark JM. 2006. The epidemiology of nonalcoholic fatty liver disease in adults. Journal of Clinical Gastroenterology. 40:S5-S10.
Cohen SE, Kokkotou E, Biddinger SB, Kondo T, Gebhardt R, Kratzsch J, Mantzoros CS, Kahn CR. 2007. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. The Journal of Biological Chemistry. 282:23672-23678.
Coppack SW, Persson M, Judd RL, Miles JM. 1999. Glycerol and nonesterified fatty acid metabolism in human muscle and adipose tissue in vivo. The American Journal of Physiology. 276:E233-E240.
Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. 2001. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 34:1158-1163.
Day CP, James OF. 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology. 4:842-845.
Day CP. 2002. Pathogenesis of steatohepatitis. Best Practice and Research Clinical Gastroenterology. 16:663-678.
Day CP. 2006. From fat to inflammation. Gastroenterology. 130:207-210.
Detlef S, Nezam H, Afdhal. 2008. Liver Cirrhosis. 371:838-851.
Deleve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. 2008. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. The American Journal of Pathology. 173:993-1001.
Dinarello CA. 2000. Proinflammatory cytokines. Chest. 118:503-508.
Dixon JB, Bhathal PS, O’Brien PE. 2006. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obesity Surgery. 16:1278-1286.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. The Journal of Clinical Investigation. 115:1343-1351.
Dowman JK, Tomlinson JW, Newsome PN. 2010. Pathogenesis of non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 103:71-83.
Eaton S, Zaitoun AM, Record CO, Bartlett K. 1996. Beta-oxidation in human alcoholic and non-alcoholic hepatic steatosis. Clinical Science. 90:307-313.
Eccleston HB, Andringa KK, Betancourt AM, King AL, Mantena SK, Swain TM, Tinsley HN, Nolte RN, Nagy TR, Abrams GA, Bailey SM. 2011. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal. 15:447-459.
Engel RW, Salmon WD. 1941. Improved diets for nutritional and pathologic studies of choline deficiency in young rats. Journal of Nutrition. 2:109-121.
Fallowfield JA. 2011. Therapeutic targets in liver fibrosis. Gastrointestinal and Liver Physiology. 300:G709-G715.
Farrell GC, Larter CZ. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43:S99-S112.
Fleming KM, Aithal GP, Card TR, West J. 2012. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver International. 32:79-84
Frederico MJ, Vitto MF, Cesconetto PA, Engelmann J, De-Souza DR, Luz G, Pinho RA, Ropelle ER, Cintra DE, De-Souza CT. 2011. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scandinavian Journal of Gastroenterology. 46:1381-1388.
Friedman SL. 2003. Liver fibrosis -- from bench to bedside. Journal of Hepatology. 38:S38-S53.
Friedman SL. 2008. Hepatic fibrosis -- overview. Toxicology. 254:120-129.
Fujita K, Nozaki Y, Yoneda M, Wada K, Takahashi H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Maeyama S, Nakajima A. 2009. Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. Alcoholism, Clinical and Experimental Research. 34:S18-S24.
Fujiyama-Fujiwara Y, Umeda-Sawada R, Kuzuyama M, Igarashi O. 1995. Effects of sesamin on the fatty acid composition of the liver of rats fed N-6 and N-3 fatty acid-rich diet. Journal of Nutritional Science and Vitaminology. 41:217-25.
Gäbele E, Brenner DA, Rippe RA. 2003. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Frontiers in Bioscience. 8:D69-D77.
Gidey YT, Kebede SA, Gashawbeza GT. 2012. Genetic diversity for morpho-agronomic traits in Ethiopian sesame landraces (Sesamum indicum L.). Asian Journal of Agricultural Research. 6:118-128.
Guturu P, Duchini A. 2012. Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. International Journal of Hepatology. 2012:2012-2020.
Harnois F, Msika S, Sabaté JM, Mechler C, Jouet P, Barge J, Coffin B. 2006. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obesity Surgery. 16:183-188.
Harte AL, Silva NF, Creely SJ, Mc-Gee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, Day CP, Mc-Ternan PG. 2010. Elevated endotoxin levels in non-alcoholic fatty liver disease. Journal of Inflammation. 7:15.
Hashimoto E, Tokushige K. 2011. Prevalence, gender, ethnic variations, and prognosis of NASH. Journal of Gastroenterology. 46:S63-S69.
Hemmann S, Graf J, Roderfeld M, Roeb E. 2007. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. Journal of Hepatology. 46:955-975.
Hirose N, Inoue T, Nishihara K, Sugano M, Akimoto K, Shimizu S, Yamada H. 1991. Inhibition of cholesterol absorption and synthesis in rats by sesamin. Journal of Lipid Research. 32:629-638.
Hsu DZ, Chen KT, Lin TH, Li YH, Liu MY. 2007. Sesame oil attenuates Cisplatin-induced hepatic and renal injuries by inhibiting nitric oxide-associated lipid peroxidation in mice. Shock. 27:199-204.
Hsu DZ, Chen KT, Chu PY, Li YH, Liu MY. 2007. Sesame oil protects against lead-plus-lipopolysaccharide-induced acute hepatic injury. Shock. 27:334-337.
Hsu DZ, Chen KT, Li YH, Chuang YC, Liu MY. 2006. Sesamol delays mortality and attenuates hepatic injury after cecal ligation and puncture in rats: role of oxidative stress. Shock. 25:528-532.
Hsu DZ, Chien SP, Chen KT, Liu MY. 2007. The effect of sesamol on systemic oxidative stress and hepatic dysfunction in acutely iron-intoxicated mice. Shock. 28:596-601.
Hsu DZ, Chu PY, Liu MY. 2009. Effect of sesame oil on acidified ethanol-induced gastric mucosal injury in rats. Journal of Parenteral and Enteral Nutrition. 33:423-427.
Hsu DZ, Li YH, Chu PY, Periasamy S, Liu MY. 2011. Sesame oil prevents acute kidney injury induced by the synergistic action of aminoglycoside and iodinated contrast in rats. Antimicrobial Agents and Chemotherapy. 55:2532-2536.
Hsu DZ, Liu CT, Li YH, Chu PY, Liu MY. 2010. Protective effect of daily sesame oil supplement on gentamicin-induced renal injury in rats. Shock. 33:88-92.
Hsu DZ, Su SB, Chien SP, Chiang PJ, Li YH, Lo YJ, Liu MY. 2005. Effect of sesame oil on oxidative-stress-associated renal injury in endotoxemic rats: involvement of nitric oxide and proinflammatory cytokines. Shock. 24:276-280.
Hou RC, Huang HM, Tzen JT, Jeng KC. 2003. Protective effects of sesamin and sesamolin on hypoxic neuronal and PC12 cells. Journal of Neuroscience Research. 74:123-133.
Ide T, Hong DD, Ranasinghe P, Takahashi Y, Kushiro M, Sugano M. 2004. Interaction of dietary fat types and sesamin on hepatic fatty acid oxidation in rats. Biochimica et Biophysica Acta. 1682:80-91.
Iredale J. 2008. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacological Research. 58:129-136.
Jie L, Fanghong L, Allan Z. 2006. Inflammation and leptin. Drug Discovery Today: Disease Mechanisms. 3:387-393
Kadayifci A, Merriman RB, Bass NM. 2007. Medical treatment of non-alcoholic steatohepatitis. Clinics in Liver Disease. 11:119-140.
Kaisho T, Akira S. 2002. Toll-like receptors as adjuvant receptors. Biochimica et Biophysica Acta. 1589:1-13.
Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, Olteanu S, Barshack I, Dotan S, Voronov E, Dinarello CA, Apte RN, Harats D. 2011. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. Journal of Hepatology. 55:1086-1094.
Kang X, Zhong W, Liu J, Song Z, Mc-Clain CJ, Kang YJ, Zhou Z. 2009. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology. 50:1241-1250.
Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, Büschenfelde KH, Blessing M. 1999. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. The American Journal of Physiology. 276:G1059-G1068.
Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. 2004. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochemical and Biophysical Research Communications. 315:187-195.
Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall PL. 2003. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. Journal of Gastroenterology and Hepatology. 18:1272-1282.
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M. 2007. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. International Journal of Molecular Medicine. 20:351-358.
Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. 2004. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Annals of Clinical and Laboratory Science. 34:57-62.
Lafontan M, Viguerie N. 2006. Role of adipokines in the control of energy metabolism: focus on adiponectin. Current Opinion in Pharmacology. 6:580-585.
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. 1996. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 23:1464-1467.
Leask A, Abraham DJ. 2004. TGF-beta signaling and the fibrotic response. FASEB Journal.18:816-827.
Li Z, Vance DE. 2008. Phosphatidylcholine and choline homeostasis. Journal of Lipid Research. 49:1187-1194.
Lim JS, Adachi Y, Takahashi Y, Ide T. 2007. Comparative analysis of sesame lignans (sesamin and sesamolin) in affecting hepatic fatty acid metabolism in rats. The British Journal of Nutrition. 97:85-95.
Longato L, Tong M, Wands JR, Monte SM. 2012. High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatology Research. 42:412-427.
Mahmood B, Ghazaleh M, Naficeh S, Mohammad RO, Behrooz J, Zahra K, Shokoufeh H, Mannan H. 2012. Profiling of major fatty acids in different raw and roasted sesame seeds cultivars. African Journal of Biotechnology. 11:6619-6623.
Makni M, Sefi M, Garoui el M, Fetoui H, Boudawara T, Zeghal N. 2011. Dietary polyunsaturated fatty acid prevents hyperlipidemia and hepatic oxidant status in pregnant diabetic rats and their macrosomic offspring. Journal of Diabetes and Its Complications. 25:267-274.
Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. 2009. Molecular mechanisms involved in NAFLD progression. Journal of Molecular Medicine. 87:679-695.
Malhi H, Kaufman RJ. 2011. Endoplasmic reticulum stress in liver disease. Journal of Hepatology. 54:795-809.
Manzoor M, Khan. 2008. Immunopharmacology. Role of Cytokines. 3:33-59.
Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. 1999. Liver pathology and the metabolic syndrome X in severe obesity. The Journal of Clinical Endocrinology and Metabolism. 84:1513-1517.
Marcolin E, Forgiarini LF, Tieppo J, Dias AS, Freitas LA, Marroni NP. 2011. Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. Arquivos de Gastroenterologia. 48:72-79.
Marí M, Colell A, Morales A, Montfort C, Garcia-Ruiz C, Fernández-Checa JC. 2010. Redox control of liver function in health and disease. Antioxidants and Redox Signaling. 12:1295-1331.
Marra F, Bertolani C. 2009. Adipokines in liver diseases. Hepatology. 50:957-969.
Martinov MV, Vitvitsky VM, Banerjee R, Ataullakhanov FI. 2010. The logic of the hepatic methionine metabolic cycle. Biochimica et Biophysica Acta. 1804:89-96.
Mato JM, Lu SC. 2007. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 45:1306-1312.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc-Cullough AJ. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116:1413-1419.
Méndez-Sánchez N, Motola-Kuba D, Bahena-Aponte J, Chavez-Tapia N, Pichardo-Bahena R, Uribe M. 2003. Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. Annals of Hepatology. 2:183-185.
Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. 2010. Etiology of liver cirrhosis in Japan: a nationwide survey. Journal of Gastroenterology. 45:86-94.
Milani S, Herbst H, Schuppan D, Kim KY, Riecken EO, Stein H. 1990. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology. 98:175-184.
Mirza MS. 2011. Obesity, visceral Fat, and NAFLD: Querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol. Article in press.
Mormone E, George J, Nieto N. 2011. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chemico Biological Interactions. 193:225-231.
Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R. 2012. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology. 56:933-42.
Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J. 2009. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scandinavian Journal of Gastroenterology. 44:358-365.
Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, Moore BB, Leff T, Reddy VD, Kondapi AK, Reddy RC. 2009. Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ. Gene Therapy and Molecular Biology. 13:20-25.
Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM. 2006. The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Free Radical Biology and Medicine. 40:341-347.
Newton JL. 2010. Systemic symptoms in non-alcoholic fatty liver disease. Digestive Diseases. 28:214-219.
Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proceedings of The National Academy of Sciences of The United States of America. 99:11482-11486.
Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. 2003. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. The Journal of Clinical Investigation. 112:608-618.
Okezie I. 1998. Free radicals, oxidative stress, and antioxidants in human health and disease. Journal of The American Oil Chemists' Society. 75:199-212.
Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U. 2010. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology. 22:18-23.
Paschos P, Paletas K. 2009. Nonalcoholic fatty liver disease two-hit process: multifactorial character of the second hit. Hippokratia.13:128.
Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. 2006. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver International. 26:151-156.
Periasamy S, Yang SS, Chen SY, Chang CC, Liu MY. 2012. Prophylactic sesame oil attenuates sinusoidal obstruction syndrome by inhibiting matrix metalloproteinase-9 and oxidative stress. Journal of Parenteral and Enteral Nutrition. Article in press.
Periasamy S, Hsu DZ, Chen SY, Yang SS, Chandrasekaran VR, Liu MY. 2011. Therapeutic sesamol attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats by inhibiting matrix metalloproteinase-9. Cell Biochem Biophys. 61:327-336.
Periasamy S, Mo FE, Chen SY, Chang CC, Liu MY. 2011. Sesamol attenuates isoproterenol-induced acute myocardial infarction via inhibition of matrix metalloproteinase-2 and -9 expression in rats. Cellular Physiology and Biochemistry. 27:273-280.
Periasamy S, Chien SP, Liu MY. 2012. Therapeutic oral sesame oil is ineffectual against monocrotaline-induced sinusoidal obstruction syndrome in rats. Journal of Parenteral and Enteral Nutrition. Article in press.
Pessayre D, Fromenty B. 2005. NASH: a mitochondrial disease. Journal of Hepatology. 42:928-940.
Pinzani M. 1999. Liver fibrosis. Seminars in Immunopathology. 21:475-490.
Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. 2008. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 48:449-457.
Postic C, Girard J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Journal of Clinical Investigation. 118:829-838.
Ramachandran P, Iredale JP. 2009. Reversibility of liver fibrosis. Annals of Hepatology. 8:283-291.
Ramachandran P, Iredale JP. 2012. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM: Monthly Journal of The Association of Physicians. 105:813-817.
Ramón B, David AB. 2005. Liver fibrosis. Journal of Clinical Investigation. 115:209-218.
Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, Ng RK, Turner SM, Badger TM, Pitas RE, Maher JJ. 2006. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. Journal of Lipid Research. 47:2280-2290.
Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. 2008. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. Journal of Lipid Research. 49:1068-1076.
Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. 2004. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transplantation. 10:886-897.
Rolo AP, Teodoro JS, Palmeira CM. 2012. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine. 52:59-69.
Rombouts K, Marra F. 2010. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. Digestive Diseases. 28:229-235.
Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. 2004. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. The Journal of Biological Chemistry. 279:32345-32353.
Sankar D, Ali A, Sambandam G, Rao R. 2011. Sesame oil exhibits synergistic effect with anti-diabetic medication in patients with type 2 diabetes mellitus. Clinical Nutrition. 30:351-358.
Sankar D, Rao MR, Sambandam G, Pugalendi KV. 2006. Effect of sesame oil on diuretics or beta-blockers in the modulation of blood pressure, anthropometry, lipid profile, and redox status. The Yale Journal of Biology and Medicine. 79:19-26.
Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. 2001. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:1183-1192.
Schattenberg JM, Galle PR. 2010. Animal models of non-alcoholic steatohepatitis: of mice and man. Digestive Diseases. 28:247-254.
Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M. 2012. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. American Journal of Physiology. Gastrointestinal and Liver Physiology. 15:G498-G506.
Schuppan D, Afdhal N. 2008. Liver cirrhosis. Lancet. 371:838-851
Seela R, Arun J, Sanyal. 2005. Evaluation and management of non-alcoholic steatohepatitis. European Journal of Gastroenterology and Hepatology. 42:S2-S12
Senoo H. 2004. Structure and function of hepatic stellate cells. Medical Electron Microscopy. 37:3-15.
Serfaty L, Lemoine M. 2008. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes and Metabolism. 34:634-637.
Seung WL, Min KJ, Min HP, Soo YL, JaeHwan L. 2010. Effects of roasting conditions of sesame seeds on the oxidative stability of pressed oil during thermal oxidation. Food Chemistry. 118:681-685.
Silva GH, Hessel G, Coelho KI, Escanhoela CA. 2011. Steatosis of indeterminate cause in a pediatric group: is it a primary mitochondrial hepatopathy? São Paulo Medical Journal. 129:217-223.
Song SC, Choi SH, Choi DW, Heo JS, Kim WS, Kim MJ. 2011. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World Journal of Gastroenterology. 17:3716-3723.
Stephen JH. 2003. The pathophysiological role of cytokines. Legal Medicine. 5:S45-S57.
Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, Mawatari H, Fujita K, Shibata W, Kirikoshi H, Maeda S, Nakajima A, Saito S. 2012. Evaluation of the liver fibrosis index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. Hepatology research. Article in press.
Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A, Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata M, Tamiya G, Ohkura T, Hibi T. 2008. Hepatic adipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology. 48:458-473.
Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gäbele E, Isayama F, Thurman RG. 2002. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. Journal of Immunology. 168:2963-2969.
Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML. 2009. Non-alcoholic steatohepatitis and animal models: understanding the human disease. The International Journal of Biochemistry and Cell Bology. 41:969-976.
Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. 2009. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 49:989-997.
Videla LA. 2009. Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World Journal of Hepatology. 1:72-78.
Visavadiya NP, Narasimhacharya AV. 2008. Sesame as a hypocholesteraemic and antioxidant dietary component. Food and Chemical Toxicology. 46:1889-1895.
Wang Z, Xu JP, Zheng YC, Chen W, Sun YW, Wu ZY, Luo M. 2011. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobiliary and Pancreatic Diseases International. 10:64-71.
Weltman MD, Farrell GC, Liddle C. 1998. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 111:1645-1653.
Whlcher JT, Evans SW. 1990. Cytokines in Disease. Clinical Chemistry. 36: 1269-1281.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 140:124-131.
Wu WH. 2007. The contents of lignans in commercial sesame oils of taiwan and their changes during heating. Food Chemistry. 104:341-344.
Yamaguchi K, Itoh Y, Yokomizo C, Nishimura T, Niimi T, Fujii H, Okanoue T, Yoshikawa T. 2010. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Laboratory Investigation. 90:1169-1178.
Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. 2007. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 45:1366-1374.
Ying Z, Kherada N, Kampfrath T, Mihai G, Simonetti O, Desikan R, Selvendiran K, Sun Q, Ziouzenkova O, Parthasarathy S, Rajagopalan S. 2011. Arteriosclerosis Thrombosis and Vascular Biology. 31:536-542.
Yu J, Chu ES, Hui AY, Cheung KF, Chan HL, Leung WK, Farrell GC, Sung JJ. 2007. Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. Biochemical and Biophysical Research Communications. 356:53-59
Zaga-Clavellina V, Garcia-Lopez G, Flores-Herrera H, Espejel-Nuñez A, Flores-Pliego A, Soriano-Becerril D, Maida-Claros R, Merchant-Larios H, Vadillo-Ortega F. 2007. In vitro secretion profiles of interleukin (IL)-1beta, IL-6, IL-8, IL-10, and TNF alpha after selective infection with Escherichia coli in human fetal membranes. Reproductive Biology and Endocrinology. 5:46-52.
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2015-01-28起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2015-01-28起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw